Stefan Oelrich has been newly elected President of the EFPIA, as new leadership calls for action to restore Europe’s global leadership in pharma innovation.

The body is eliminating of Risk Evaluation and Mitigation Strategies for all currently approved BCMA- and CD19-directed CAR T-cell therapies.

Ascroft brings more than 30 years of industry experience, including senior roles at Takeda Pharmaceuticals.

The US plans to stop its financial contributions to Gavi, the Vaccine Alliance, marking an end to an over 20-year partnership.

The survey found that, while 57% of patients support the use of AI in the examination room, they are less enthusiastic about diagnostics.

The FDA has launched an immediate review of clinical trials involving the export of American patients’ living cells to China and other “hostile countries”.

A UK project has received a £1.8m to transform how medicines are made, aiming to make drug manufacturing faster, cleaner and more responsive.

The UK government has set out a 10 Year Health Plan, promising to transform clinical trials and make the UK a scientific superpower.

A £300m bond has been issued by the International Finance Facility for Immunisation to fund vaccine programmes in lower-income countries.

New Ipsos data shows that while 58% of UK adults are willing to join clinical trials, this drops to 41% among ethnic minority adults.

The UK will hike statutory payment rates for branded drugs to over 30% in 2025, far surpassing other European markets and raising concerns.

According to new research from the ABPI, pharma companies need to modernise their outreach strategies.

Vantive has announced the five-year, major investment to expand its R&D and manufacturing capabilities.

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

The King’s Fund in the UK has released an updated explainer on the availability of new medicines in the UK’s NHS.

The Paris biotech aims to improve biologic drugs by mastering glycan control, aiming for safer, more effective therapies.

Catch up on May’s key pharma news, research updates and policy shifts.

BioNTech is set to invest up to £1bn in the UK over the next decade, establishing new R&D and AI hubs.

Experts have pointed to the climate crisis as a potential trigger of the West Nile Virus finding.

Dr Tedros sets out WHO’s next steps on pandemic preparedness, climate action and AMR during the 78th World Health Assembly in Geneva.

Colorectal cancer now has the most real-world data, but Phesi warns clinical trials are lagging behind.

WHAM’s Innovator’s Circle unites top funds to address the women’s health investment gap.

Trump’s “most-favoured nation” drug pricing plan shakes pharma markets, sparking losses for US and EU firms.

The initiative is set to revolutionise healthcare delivery and agricultural exports in low- and middle-income countries.

Gallman takes on the role of EVP, General Counsel and Chief Policy Officer, following Sandra Leung’s retirement after 33 years.

From new scientific data-sharing initiatives to US drug tariffs, May brought a range of major news to the pharma landscape.

Eli Lilly joins forces with Alchemab in a deal worth $415m, expanding its neuroscience pipeline with a novel candidate.

Generation Gold Standard is a universal vaccine platform targeting influenza, coronaviruses and future pandemics.

Novartis announces acquisition of Regulus Therapeutics, adding a potential first-in-class miR-17 inhibitor to its renal pipeline.

ViiV leads the 2024/25 pharma company reputation rankings, with the PatientView report also finding ways to improve.

Ireland has launched its first national clinical genomics study in paediatric oncology.

Boehringer Ingelheim and Tessellate Bio form a €500m partnership to develop precision therapies.

US drug tariffs may not hit branded prices hard, but generics and supply chains face disruption. Here’s what pharma leaders need to know.

FluidForm Bio’s 3D bioprinting tech keeps lab-grown cells alive five times deeper using vascular-like gelatin scaffolds.

The UK government has formally signed into law new clinical trial regulations, designed to modernise operations across the country.

CloudSpec speeds up lipid nanoparticle analysis, cutting lab times from hours to seconds for gene therapy and vaccine research.

The UK government has announced a significant new initiative to accelerate drug discovery and improve patient care in the country.  

Pharma must balance creativity with transparency to rebuild trust in 2025. VML Health’s report reveals key trends shaping expectations.

Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an expanded role.

From the latest news impacting the UK’s NHS to large industry acquisitions, March brought a range of impactful news.